Willemijn S.M.E. Theelen

机构：Dutch Cancer Society, The Netherlands Cancer Institute, Oncode Institute, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital · ORCID：0000-0001-9772-0511

发表论文 123 篇 · 总被引 7041 次 · h-index 22

代表论文

• Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer (2025 · Nature Cancer · 被引 59)
• First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study. (2025 · Journal of Clinical Oncology · 被引 25)
• Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better? (2025 · Journal for ImmunoTherapy of Cancer · 被引 8)
• Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer (2025 · ESMO Open · 被引 8)
• Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study (2025 · Lung Cancer · 被引 2)
• Enrichment of SMARCA4 mutations in lung carcinomas presenting as cancer of unknown primary (2026 · Lung Cancer · 被引 1)